InFACT: a global critical care research response to H1N1

By early October, 2009, there had been more than 340 000 reported cases of H1N1 infection in 191 countries, with more than 4100 deaths.1 WHO initially projected that up to 2 billion people could become infected with the virus over the next 2 years.2 Although vaccination programmes and other factors...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2010-01, Vol.375 (9708), p.11-13
Main Authors: The InFACT Global H1N1 Collaboration, InFACT Global H1N1 Collaboration
Format: Article
Language:English
Subjects:
Antiviral agents
Corticoids
Critical Care
Humans
Illnesses
Influenza A Virus, H1N1 Subtype
Influenza, Human - therapy
Intensive care
Internal Medicine
Mortality
Statins
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:By early October, 2009, there had been more than 340 000 reported cases of H1N1 infection in 191 countries, with more than 4100 deaths.1 WHO initially projected that up to 2 billion people could become infected with the virus over the next 2 years.2 Although vaccination programmes and other factors should reduce this number, plausible estimates of the number of infected individuals who might benefit from admission to intensive care range from 200 000 to 10 million. Beyond antiviral agents, anecdotal reports and data from animal studies suggest that illness severity can be attenuated by readily available agents, such as corticosteroids and statins, that can modulate the host's inflammatory response.9 None of these drugs has been adequately studied for efficacy.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(09)61792-X